Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004199 · ClinicalTrials.gov registry record · Phase 3
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004199: Completed Phase 3 study, sponsored by Pfizer.
NCT00004199 is a Phase 3 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004199, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus cisplatin and gemcitabine in treating patients who have metastatic or recurrent non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
- DRUG prinomastat
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Phase | Phase 3 |
What the finished NCT00004199 record still lists
NCT00004199 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00004199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004199 about?
NCT00004199 is a clinical study titled "Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer". RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus cisplatin and g...
What is the current status of trial NCT00004199?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-03.
What interventions are being tested in trial NCT00004199?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG), prinomastat (DRUG).
Who is sponsoring clinical trial NCT00004199?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia